NAD+
NAD+
Multi-buy savings: save 4% on 2+ items and 6% on 3+. Applied automatically in your cart.
Couldn't load pickup availability
- Same-day dispatch on orders before 2pm, Royal Mail Tracked
- Free UK shipping on orders over £100
- Certificate of Analysis with every order · Request CoA
- For in vitro laboratory research use only
Concentration calculator
For laboratory calculation only. Not for human or veterinary use.
NAD⁺ (Nicotinamide Adenine Dinucleotide) (CAS 53-84-9) is a fundamental coenzyme present in all living cells, functioning as an electron carrier in redox reactions and as a substrate for a broad class of enzymes including sirtuins (SIRT1–7), PARPs (poly ADP-ribose polymerases), and CD38. NAD⁺ levels decline with age and in conditions of metabolic stress, linking it to aging biology, DNA repair capacity, mitochondrial function, and circadian rhythm regulation.
In research settings, NAD⁺ is studied as a substrate for sirtuin-mediated deacetylation reactions, a regulator of PARP-1-dependent DNA damage responses, and a mediator of calcium signalling via CD38/cADPR pathways. Supplementation studies have investigated its role in restoring mitochondrial function, improving insulin sensitivity, and modulating the aging transcriptome in model organisms.
Specifications
| CAS | 53-84-9 |
|---|---|
| Formula | C21H27N7O14P2 |
| MW | 663.4 g/mol |
| Purity | ≥98% |
| Format | Lyophilised powder |
| Storage | −20 °C |
Research areas
- Sirtuin substrate biology
- PARP-1 / DNA repair
- Mitochondrial bioenergetics
- Aging & longevity research
- Metabolic regulation
- Circadian rhythm
- CD38 signalling
Selected literature
Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.
Share
